EN DE
Watch BSF Enterprise Plc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

BSF Enterprise Plc (BSFA) fair value: what the stock is really worth

As of Nov 12, 2026: fair value (intrinsic value) of BSF Enterprise Plc stock £0.01, price £0.01, that is 7.0% below the price, quality 29 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare GB · ISIN GB00BHNBDQ51

BE BSF Enterprise Plc logo Thin data Nov 10, 2026

BSF Enterprise Plc

BSFA · LSE

The stock is already about fairly priced and weak company.

Get notified free when this changes
Fair value £0.0100 · Fairly valued 
Revenue last quarter 9% below a year ago. 
Quality 29/100 
Weak Growth (revenue YoY −8.6 %/yr in GBP) 
Negative free cash flow 
Trails peers (2/7) 
Narrow moat 10/100 · thin data
Thin data 
Estimate
Watch BSF Enterprise Plc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

£30.82 £0.0060 Fair Value £0.0100 Nov 2020 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range £0.0060 – £30.82 · fair‑value band £0.0098 – £0.0102 · the £0.0108 price screens above the £0.0100 fair value. As of Nov 10, 2026.

Follow BSF Enterprise in your weekly email

Every Wednesday you see whether BSF Enterprise is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

BSF Enterprise Plc, together with its subsidiaries, develops and commercializes cell-based tissue engineering solutions in the United Kingdom and Hong Kong. The company acquires businesses in the biotechnology, marketing, and e-commerce sectors.

Show moreShow less

It also engages in biotechnology start-up; lab-grown cornea and meat research; and development of skin technology. The company was incorporated in 2018 and is based in London, the United Kingdom.

Stock analysis

BSF Enterprise Plc (BSFA) currently trades at £0.0108, while our estimate is £0.0100, so the stock looks roughly fairly valued today (gap 7.5%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: £0.0098 (bear) to £0.0102 (bull), the price of £0.0108 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

BSF Enterprise Plc reported revenue of £52.8K in FY2025 versus £0 in FY2021. Reported net income was −£1.1M in FY2025.

Key figures

Market cap £2.2M Micro · P/S ratio 35.9 · EPS (TTM) £−0.0100 · Return on equity −55.0% · Return on assets (EBIT) −34.6% (5-year average) · Operating margin −5,383% · Revenue (TTM) £51.1K · Revenue growth (YoY) −8.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 100% below its 52-week high and 79% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −7%, BSFA screens cheaper than that median.

Fair Value

Bear £0.0098 Fair Value £0.0100 Bull £0.0102
Price £0.0108 · Downside -7.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 29/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 50
Are margins and returns getting better?
Cashflow 9
Do the profits arrive as real cash?
Financial strength 54
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 14
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 14
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch BSFA, get fair value alerts →

Compare BSF Enterprise Plc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside −7.0% · Top 25%
Profitability
Return on assets −37.0% · Below median
Growth and dividend
Revenue growth (quarter YoY) −8.6% · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.81× · Cheapest 25%
P/S (12 months) 42.91× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)24 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $951.19 $1,275 +34% vs BSFA
Vertex Pharmaceuticals Incorporated VRTX $542.62 $602.68 +11% vs BSFA
Genmab A/S GMAB kr 3,530 kr 3,917 +11% vs BSFA
Samsung Biologics Co 207940 1,449,000 KRW 1,573,000 KRW +9% vs BSFA
argenx SE ARGX $981.33 $908.40 −7% vs BSFA
CSL Limited CSL A$202.92 A$183.54 −10% vs BSFA
Moderna, Inc MRNA $231.35 $139.99 −39% vs BSFA
BeOne Medicines AG 6160 HK$255.80 HK$152.80 −40% vs BSFA
Celltrion, Inc 068270 209,500 KRW 74,945 KRW −64% vs BSFA
Royalty Pharma plc RPRX $68.97 $19.01 −72% vs BSFA

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

BSF Enterprise Plc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "BSF Enterprise Plc Fair Value". https://www.fairvalue-calculator.com/stock/BSFA

Frequently asked questions

Is BSF Enterprise Plc (BSFA) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is £0.0100 versus a price of £0.0108, about 7% lower (fairly valued).
What is the fair value of BSFA?
Our estimate for BSF Enterprise Plc is £0.0100 (as of Nov 10, 2026), built from audited fundamentals. The current price: £0.0108.
What is the quality score of BSFA?
BSF Enterprise Plc has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BSF Enterprise Plc (BSFA)?
Our calculated price target is the estimate of £0.0100 (as of Nov 10, 2026). Cautious scenario £0.0098, optimistic scenario £0.0102. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the BSF Enterprise Plc stock forecast for 2026?
Our estimate puts fair value at £0.0100, about 7% lower versus a price of £0.0108 (fairly valued). Cautious scenario £0.0098, optimistic scenario £0.0102. The calculation is refreshed regularly with new filings.
What is the revenue of BSF Enterprise Plc (BSFA)?
BSF Enterprise Plc reported trailing-twelve-month revenue of about £51.1K (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of BSF Enterprise Plc (BSFA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BSF Enterprise Plc it is £0.0100 per share (as of Nov 10, 2026), against a price of £0.0108.
Is BSF Enterprise Plc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, BSFA trades above its calculated fair value: price £0.0108, fair value £0.0100, a gap of about −7% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BSFA?
No. The price is what the market pays today (£0.0108); the fair value is what the company's own numbers justify (£0.0100). For BSF Enterprise Plc the two are £0.0007 per share apart. That gap is exactly why we show both numbers side by side.
How much is BSF Enterprise Plc worth?
The market values BSF Enterprise Plc at about £2.2M (market capitalisation, as of Nov 10, 2026). Per share that is £0.0108; our models calculate a fair value of £0.0100 per share.
What do the bullish and bearish scenarios say about BSFA?
Our models span a range for BSF Enterprise Plc: cautious scenario £0.0098, base £0.0100, optimistic £0.0102 per share (as of Nov 10, 2026, price £0.0108). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of BSF Enterprise Plc (BSFA)?
Balance-sheet figures for BSF Enterprise Plc (as of Nov 10, 2026): return on equity −55.0%. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is BSFA from its 52-week high?
BSF Enterprise Plc trades at £0.0108, about 100% below its 52-week high of £4.18 and 79% above the low of £0.0060 (as of Nov 12, 2026). Distance from the high says nothing about value: that is what the fair value of £0.0100 is for.
Which stocks are comparable to BSF Enterprise Plc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BSF Enterprise Plc stock attractive at the current price?
The data as of Nov 10, 2026: price £0.0108, calculated fair value £0.0100 (−7%), Quality Score 29/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.3% above its aggregate fair value. BSF Enterprise Plc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BSF Enterprise Plc (BSFA)?
The closing price on Nov 12, 2026 was £0.0108. Our estimate is £0.0100, about 7% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BSF Enterprise Plc right now?
The price sits above even our optimistic bull case (£0.0102). The favourable scenario is already priced in. The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band (£0.0098 to £0.0102), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of BSF Enterprise Plc

How large is the market capitalisation of BSF Enterprise Plc (BSFA)?
The market capitalisation of BSF Enterprise Plc is £2.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BSF Enterprise Plc (BSFA)?
The price-to-sales ratio of BSF Enterprise Plc is 35.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BSF Enterprise Plc (BSFA)?
Earnings per share at BSF Enterprise Plc are £−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of BSF Enterprise Plc (BSFA)?
The return on equity (ROE) of BSF Enterprise Plc is −55.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BSF Enterprise Plc (BSFA)?
On an EBIT basis the return on assets of BSF Enterprise Plc is −34.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BSF Enterprise Plc (BSFA)?
The operating margin of BSF Enterprise Plc is −5,383% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BSF Enterprise Plc (BSFA)?
Revenue at BSF Enterprise Plc is growing −8.6% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does BSF Enterprise Plc (BSFA) generate?
The free cash flow of BSF Enterprise Plc is −£1.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does BSF Enterprise Plc (BSFA) hold?
BSF Enterprise Plc holds more cash than debt, £149K net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch BSF Enterprise Plc in the live analysis

One click puts BSF Enterprise Plc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.